Valuation: ALLOVIRPAR

Market Cap 4.92Cr 4.38Cr 4.06Cr 3.68Cr 6.91Cr 466.19Cr 7.03Cr 49Cr 19Cr 243.97Cr 18Cr 18Cr 778.29Cr P/E 2023
-0.37x
P/E 2024 -0.82x
Enterprise Value -6.91Cr -6.15Cr -5.7Cr -5.16Cr -9.7Cr -654.39Cr -9.87Cr -68Cr -27Cr -342.45Cr -26Cr -25Cr -1.09TCr EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
-
Yield 2023 *
-
Yield 2024 -
1 day+8.38%
Current month-78.90%
Current year-78.90%
3 years 1.9
Extreme 1.9
57.15
5 years 1.9
Extreme 1.9
576.38
10 years 1.9
Extreme 1.9
1,126.08

Financials

2023 2024
Net sales - -
Net income -19Cr -17Cr -16Cr -14Cr -27Cr -1.8TCr -27Cr -188.49Cr -74Cr -944Cr -71Cr -70Cr -3.01TCr -5.88Cr -5.23Cr -4.85Cr -4.39Cr -8.26Cr -556.74Cr -8.39Cr -58Cr -23Cr -291.35Cr -22Cr -22Cr -929.44Cr
Net Debt -16Cr -14Cr -13Cr -12Cr -22Cr -1.48TCr -22Cr -154.93Cr -61Cr -775.92Cr -59Cr -57Cr -2.48TCr -12Cr -11Cr -9.76Cr -8.84Cr -17Cr -1.12TCr -17Cr -117.09Cr -46Cr -586.42Cr -44Cr -43Cr -1.87TCr
Projected Income Statement - Annual - ALLOVIRPAR
Logo ALLOVIRPAR
AlloVir, Inc. is an allogeneic T cell immunotherapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The company’s proprietary technology platforms leverage off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. Its technology and manufacturing process enable the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. Its lead product candidate, posoleucel, is a multi-VST therapy that targets six viruses: adenovirus (BKV), cytomegalovirus (EBV), human herpesvirus 6 (HHV-6) and JC virus (JCV). Its proprietary VST manufacturing platform enables the rapid, robust and reproducible generation of single-virus and multi-virus specific cell therapeutic candidates for clinical use.
Employees
6
Sector
-
Date Price Change
21/26/21 $2.070 +8.38%
19/26/19 $1.910 -4.50%
16/26/16 $2.000 -8.68%
15/26/15 $2.190 +2.82%
14/26/14 $2.130 -4.48%
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
  1. Stock Market
  2. Stocks
  3. ALVR Stock